🚀 VC round data is live in beta, check it out!
BeyondSpring Valuation Multiples
Discover revenue and EBITDA valuation multiples for BeyondSpring and similar public comparables like XBiotech, IBT, InflaRx, PMV Pharma and more.
BeyondSpring Overview
About BeyondSpring
BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment.
Founded
2014
HQ
Employees
40
Website
Sectors
Financials (FY)
EV
$59M
BeyondSpring Financials
BeyondSpring reported last fiscal year revenue of — and negative EBITDA of ($9M).
In the same fiscal year, BeyondSpring generated ($9M) in EBITDA losses and had net loss of ($1M).
Revenue (LTM)
BeyondSpring P&L
In the most recent fiscal year, BeyondSpring reported revenue of — and EBITDA of ($9M).
BeyondSpring expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($9M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($1M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BeyondSpring Stock Performance
BeyondSpring has current market cap of $72M, and enterprise value of $59M.
Market Cap Evolution
BeyondSpring's stock price is $1.74.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $59M | $72M | -2.8% | XXX | XXX | XXX | $-0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBeyondSpring Valuation Multiples
BeyondSpring trades at (6.7x) EV/EBITDA.
EV / Revenue (LTM)
BeyondSpring Financial Valuation Multiples
As of April 11, 2026, BeyondSpring has market cap of $72M and EV of $59M.
Equity research analysts estimate BeyondSpring's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BeyondSpring has a P/E ratio of (71.1x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $72M | XXX | $72M | XXX | XXX | XXX |
| EV (current) | $59M | XXX | $59M | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (6.7x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (6.6x) | XXX | XXX | XXX |
| P/E | — | XXX | (71.1x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BeyondSpring Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BeyondSpring Margins & Growth Rates
BeyondSpring's revenue in the last fiscal year declined by (100%).
BeyondSpring's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.
BeyondSpring Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 5% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BeyondSpring Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| XBiotech | XXX | XXX | XXX | XXX | XXX | XXX |
| IBT | XXX | XXX | XXX | XXX | XXX | XXX |
| InflaRx | XXX | XXX | XXX | XXX | XXX | XXX |
| PMV Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fractyl Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BeyondSpring M&A Activity
BeyondSpring acquired XXX companies to date.
Last acquisition by BeyondSpring was on XXXXXXXX, XXXXX. BeyondSpring acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BeyondSpring
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBeyondSpring Investment Activity
BeyondSpring invested in XXX companies to date.
BeyondSpring made its latest investment on XXXXXXXX, XXXXX. BeyondSpring invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BeyondSpring
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BeyondSpring
| When was BeyondSpring founded? | BeyondSpring was founded in 2014. |
| Where is BeyondSpring headquartered? | BeyondSpring is headquartered in United States. |
| How many employees does BeyondSpring have? | As of today, BeyondSpring has over 40 employees. |
| Who is the CEO of BeyondSpring? | BeyondSpring's CEO is Lan Huang. |
| Is BeyondSpring publicly listed? | Yes, BeyondSpring is a public company listed on Nasdaq. |
| What is the stock symbol of BeyondSpring? | BeyondSpring trades under BYSI ticker. |
| When did BeyondSpring go public? | BeyondSpring went public in 2017. |
| Who are competitors of BeyondSpring? | BeyondSpring main competitors are XBiotech, IBT, InflaRx, PMV Pharma. |
| What is the current market cap of BeyondSpring? | BeyondSpring's current market cap is $72M. |
| Is BeyondSpring profitable? | No, BeyondSpring is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.